
Sagimet Biosciences Inc. – NASDAQ:SGMT
Sagimet Biosciences stock price today
Sagimet Biosciences stock price monthly change
Sagimet Biosciences stock price quarterly change
Sagimet Biosciences stock price yearly change
Sagimet Biosciences key metrics
Market Cap | 149.38M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.34 |
Revenue | N/A |
EBITDA | -32.74M |
Income | -27.91M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSagimet Biosciences stock price history
Sagimet Biosciences stock forecast
Sagimet Biosciences financial statements
Jun 2023 | 0 | -6.78M | |
---|---|---|---|
Sep 2023 | 2M | -6.35M | -317.65% |
Dec 2023 | 0 | -8.15M | |
Mar 2024 | 0 | -6.62M |
2025 | 2M | -116.40M | -5820.4% |
---|---|---|---|
2026 | 2M | -181.28M | -9064.47% |
Analysts Price target
Financials & Ratios estimates
2024-03-25 | -0.62 | -0.78 |
---|---|---|
2024-05-15 | -0.41 | -0.23 |
Jun 2023 | 21498000 | 219.91M | 1022.94% |
---|---|---|---|
Sep 2023 | 102925000 | 5.05M | 4.91% |
Dec 2023 | 96719000 | 5.65M | 5.85% |
Mar 2024 | 194528000 | 4.51M | 2.32% |
Jun 2023 | -5.72M | 12.8M | -910K |
---|---|---|---|
Sep 2023 | -3.87M | 0 | 87.21M |
Dec 2023 | -7.08M | -19.62M | 3.51M |
Mar 2024 | -6.20M | 3M | 104.84M |
Sagimet Biosciences alternative data
Dec 2023 | 9 |
---|---|
Jan 2024 | 9 |
Feb 2024 | 9 |
Mar 2024 | 8 |
Apr 2024 | 8 |
May 2024 | 8 |
Jun 2024 | 8 |
Jul 2024 | 8 |
Sagimet Biosciences other data
Period | Buy | Sel |
---|---|---|
Jul 2023 | 30000 | 662 |
Mar 2024 | 12100 | 0 |
Undercovered Dozen: Fannie Mae, Civitas Resources, LifeVantage, ZenaTech +
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China
Sagimet: Additional Upside Possible After Latest NASH Data Release
-
What's the price of Sagimet Biosciences stock today?
One share of Sagimet Biosciences stock can currently be purchased for approximately $7.04.
-
When is Sagimet Biosciences's next earnings date?
Unfortunately, Sagimet Biosciences's (SGMT) next earnings date is currently unknown.
-
Does Sagimet Biosciences pay dividends?
No, Sagimet Biosciences does not pay dividends.
-
How much money does Sagimet Biosciences make?
Sagimet Biosciences has a market capitalization of 149.38M. Sagimet Biosciences made a loss 27.88M US dollars in net income (profit) last year or -$0.23 on an earnings per share basis.
-
What is Sagimet Biosciences's stock symbol?
Sagimet Biosciences Inc. is traded on the NASDAQ under the ticker symbol "SGMT".
-
What is Sagimet Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sagimet Biosciences?
Shares of Sagimet Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Sagimet Biosciences have?
As Jul 2024, Sagimet Biosciences employs 8 workers.
-
When Sagimet Biosciences went public?
Sagimet Biosciences Inc. is publicly traded company for more then 2 years since IPO on 17 Jul 2023.
-
What is Sagimet Biosciences's official website?
The official website for Sagimet Biosciences is sagimet.com.
-
Where are Sagimet Biosciences's headquarters?
Sagimet Biosciences is headquartered at 155 Bovet Road, San Mateo, CA.
-
How can i contact Sagimet Biosciences?
Sagimet Biosciences's mailing address is 155 Bovet Road, San Mateo, CA and company can be reached via phone at +65 05618600.
Sagimet Biosciences company profile:

Sagimet Biosciences Inc.
sagimet.comNASDAQ
8
Biotechnology
Healthcare
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
San Mateo, CA 94402
CIK: 0001400118
ISIN: US7867001049
CUSIP: 786700104